Cover Story: Chinese Biotech Is Having a ‘DeepSeek Moment’
A flurry of multibillion-dollar deals marks China’s emergence as a leading force in the innovative drug sector
In a resounding vote of confidence in China’s biotechnology sector, leading global pharmaceutical companies are striking multi-billion-dollar deals for innovative therapies developed by Chinese firms. These deals mark a pivotal point for China’s role in global drug development and have sparked a capital market frenzy.
In late May, Pfizer Inc. agreed to pay $1.25 billion upfront to 3SBio Inc., a Shenyang-based biotech firm, for the rights to a promising anti-tumor drug. The agreement could eventually be worth up to $6.05 billion.
Two weeks later,
Keep reading with a 7-day free trial
Subscribe to Caixin Global China Watch to keep reading this post and get 7 days of free access to the full post archives.